Dual Targeting of GPRC5D and BCMA Gets High Response Rate in Extramedullary Myeloma

(MedPage Today) — ORLANDO — For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination of talquetamab (Talvey) and teclistamab (Tecvayli) achieved high response rates in updated results…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118891

Author :

Publish date : 2025-12-08 19:32:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Dual Targeting of GPRC5D and BCMA Gets High Response Rate in Extramedullary Myeloma

Odd elements in supernova blast might have implications for alien life

Trial Results Could Shuffle Order of BTK Inhibitors for CLL/SLL

Related Posts

Botox, Trulicity, and 13 Other Drugs Selected for Medicare Price Negotiation

Charities Warn UK Youth Are ‘Europe’s Unhappiest’

The Rear View: How Glute Shape Predicts Diabetes Risk

Stroke Now Ranks Fourth as a Leading Cause of Death

Indoor Ice Air a Health Concern Ahead of 2026 Olympics

Woman ‘took own life after benefits cut in error’

Charities Warn UK Youth Are ‘Europe’s Unhappiest’

The Rear View: How Glute Shape Predicts Diabetes Risk

Stroke Now Ranks Fourth as a Leading Cause of Death

Indoor Ice Air a Health Concern Ahead of 2026 Olympics

Woman ‘took own life after benefits cut in error’

Are Nicotine Pouches a Cassation Tool?

Diabetologists On the Rise as Disease Overwhelms Practices

Daily AI Use Linked to Higher Risk for Depressive Symptoms

Categories

Archives